Cargando…

Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera

The majority of cervical cancers are associated with infection by one or more Human Papillomavirus (HPV) types from just two distinct Alpha-Papillomavirus species groups, A7 and A9. The extent to which the current HPV16/18 vaccines will protect against other genetically related HPV types is of inter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Draper, Eve, Bissett, Sara L., Howell-Jones, Rebecca, Edwards, Debbie, Munslow, Graham, Soldan, Kate, Beddows, Simon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science 2011
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3359499/ https://www.ncbi.nlm.nih.gov/pubmed/21939712 http://dx.doi.org/10.1016/j.vaccine.2011.09.021

Ejemplares similares

Sensitivity of Human Papillomavirus (HPV) Lineage and Sublineage Variant Pseudoviruses to Neutralization by Nonavalent Vaccine Antibodies
por: Godi, Anna, et al.
Publicado: (2019)

A Randomized, Observer-Blinded Immunogenicity Trial of Cervarix(®) and Gardasil(®) Human Papillomavirus Vaccines in 12-15 Year Old Girls
por: Draper, Eve, et al.
Publicado: (2013)

Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study
por: Mesher, David, et al.
Publicado: (2016)

Cross-neutralizing antibodies elicited by the Cervarix(®) human papillomavirus vaccine display a range of Alpha-9 inter-type specificities()
por: Bissett, Sara L., et al.
Publicado: (2014)

Human papillomavirus (HPV) in young women in Britain: Population-based evidence of the effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types
por: Tanton, Clare, et al.
Publicado: (2017)

The impact of catch-up bivalent human papillomavirus vaccination on cervical screening outcomes: an observational study from the English HPV primary screening pilot
por: Rebolj, Matejka, et al.
Publicado: (2022)

Bivalent Human Papillomavirus (HPV) Vaccine Effectiveness Correlates With Phylogenetic Distance From HPV Vaccine Types 16 and 18
por: Bogaards, Johannes A, et al.
Publicado: (2019)

Human papillomavirus (HPV) vaccination and oropharyngeal HPV in ethnically diverse, sexually active adolescents: community-based cross-sectional study
por: Kerry-Barnard, Sarah, et al.
Publicado: (2021)

Potential health impact and cost-effectiveness of bivalent human papillomavirus (HPV) vaccination in Afghanistan
por: Anwari, Palwasha, et al.
Publicado: (2020)

Vaccination with Human Papillomavirus Pseudovirus-Encapsidated Plasmids Targeted to Skin Using Microneedles
por: Kines, Rhonda C., et al.
Publicado: (2015)

Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix(®) or Gardasil(®) Vaccine
por: Godi, Anna, et al.
Publicado: (2015)

Mucosal Delivery of Human Papillomavirus Pseudovirus-Encapsidated Plasmids Improves Potency of DNA Vaccination
por: Graham, Barney S., et al.
Publicado: (2010)

The DE and FG loops of the HPV major capsid protein contribute to the epitopes of vaccine-induced cross-neutralising antibodies
por: Bissett, Sara L., et al.
Publicado: (2016)

Application of pseudovirus system in the development of vaccine, antiviral-drugs, and neutralizing antibodies
por: Xiang, Qi, et al.
Publicado: (2022)

Amino acid sequence diversity of the major human papillomavirus capsid protein: Implications for current and next generation vaccines()
por: Ahmed, Amina I., et al.
Publicado: (2013)

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera
por: Muik, Alexander, et al.
Publicado: (2021)

Epidemiology of genital warts in the British population: implications for HPV vaccination programmes
por: Sonnenberg, Pam, et al.
Publicado: (2019)

Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines
por: Mariz, Filipe Colaço, et al.
Publicado: (2020)

Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial
por: Panagiotou, Orestis A, et al.
Publicado: (2015)

Vaccine Effectiveness Following Routine Immunization With Bivalent Human Papillomavirus (HPV) Vaccine: Protection Against Incident Genital HPV Infections From a Reduced-Dosing Schedule
por: Hoes, Joske, et al.
Publicado: (2021)

Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins
por: Bissett, Sara L., et al.
Publicado: (2014)

Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica
por: Herrero, Rolando, et al.
Publicado: (2013)

Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females
por: Harper, Diane M., et al.
Publicado: (2011)

Oral human papillomavirus (HPV) infection in men who have sex with men: prevalence and lack of anogenital concordance
por: King, Eleanor M, et al.
Publicado: (2015)

Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development
por: Pinto, Ligia A., et al.
Publicado: (2018)

Predictors of the Therapeutic Response to Intralesional Bivalent HPV Vaccine in Wart Immunotherapy
por: Hammad, Noha M., et al.
Publicado: (2021)

Cost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

Vaccinating Women Previously Exposed to Human Papillomavirus: A Cost-Effectiveness Analysis of the Bivalent Vaccine
por: Turner, Hugo C., et al.
Publicado: (2013)

Impact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis
por: Cuschieri, K, et al.
Publicado: (2016)

Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials
por: Wacholder, Sholom, et al.
Publicado: (2010)

Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England()
por: Mesher, D., et al.
Publicado: (2013)

Effect of the bivalent HPV vaccine on viral load of vaccine and non-vaccine HPV types in incident clearing and persistent infections in young Dutch females
por: van der Weele, Pascal, et al.
Publicado: (2019)

Evaluation of antigenic differences between wild and Sabin vaccine strains of poliovirus using the pseudovirus neutralization test
por: Arita, Minetaro, et al.
Publicado: (2019)

Evidence for single-dose protection by the bivalent HPV vaccine—Review of the Costa Rica HPV vaccine trial and future research studies
por: Kreimer, Aimée R., et al.
Publicado: (2018)

Direct, indirect and total effectiveness of bivalent HPV vaccine in women in Galicia, Spain
por: Purriños-Hermida, M. Jesus, et al.
Publicado: (2018)

Safety and immunogenicity of a bivalent HPV16/18 vaccine in Chinese females
por: Shi, Li-Wei, et al.
Publicado: (2023)

Neutralization of Omicron Subvariant BA.2.75 after Bivalent Vaccination
por: Chalkias, Spyros, et al.
Publicado: (2022)

Characterization of human papillomavirus type 16 pseudovirus containing histones
por: Kim, Hyoung Jin, et al.
Publicado: (2016)

Gaps in detailed knowledge of human papillomavirus (HPV) and the HPV vaccine among medical students in Scotland
por: McCusker, Sarah M, et al.
Publicado: (2013)

Contribution of Surface-Exposed Loops on the HPV16 Capsid to Antigenic Domains Recognized by Vaccine or Natural Infection Induced Neutralizing Antibodies
por: Godi, Anna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3qdjgovbffe63hfsnmi26eupi3